BGHL (GBP): NAV(s)

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
53
BGHL (GBP): NAV(s)

                                      BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary Shares

The Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.

 

Close of business 26 Jun 2018.

 

Estimated NAV

 

  Euro Shares Sterling Shares
Estimated NAV €  23.6854 £  21.0017
Estimated MTD return  0.14 %  0.20 %
Estimated YTD return  1.02 %  1.42 %
Estimated ITD return  136.85 %  110.02 %

 

NAV and returns are calculated net of management and performance fees

 

Market information

 

Euro Shares Amsterdam (AEX) London (LSE)
Market Close €  19.80 N/A
Premium/discount to estimated NAV  -16.40 % N/A
     
Sterling Shares Amsterdam (AEX) London (LSE)
Market Close N/A GBX 1,735.00
Premium/discount to estimated NAV N/A  -17.39 %

 

 

Transactions in own securities purchased into treasury

 

Ordinary Shares Euro Shares Sterling Shares
Number of shares N/A N/A
Average Price N/A N/A
Range of Price N/A N/A

           

                                           

Liquidity Enhancement Agreement Euro Shares Sterling Shares
Number of shares N/A N/A
Average Price N/A N/A

 

BGHL Capital

 

BGHL Ordinary Shares Euro Shares Sterling Shares
Shares Outstanding  28,758,219  632,590
Held in treasury N/A N/A
Shares Issued  28,758,219  632,590

 

Estimated BG Fund NAV

Class B Euro Shares (estimated) €  190.5104

The Class B Euro Shares of BG Fund are not subject to investment manager fees, as the Investment Manager receives management fees and performance fees in respect of its role as Investment Manager of BGHL.

 

For further information please contact:

Boussard & Gavaudan Investment Management, LLP. Emmanuel Gavaudan +44 (0) 20 3751 5389 Email : info@bgam-uk.com

 

The Company is established as a closed-ended investment company domiciled in Guernsey. The Company has received the necessary approval of the Guernsey Financial Services Commission and the States of Guernsey Policy Council. The Company is registered with the Dutch Authority for the Financial Markets as a collective investment scheme pursuant to article 2:73 in conjunction with 2:66 of the Dutch Financial Supervision Act (Wet op het financieel toezicht). The shares of the Company (the "Shares") are listed on Euronext Amsterdam. The Shares are also listed on the Official List of the UK Listing Authority and admitted to trading on the London Stock Exchange plc's main market for listed securities.

This is not an offer to sell or a solicitation of any offer to buy any securities in the United States or in any other jurisdiction. This announcement is not intended to and does not constitute, or form part of, any offer or invitation to purchase any securities or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law.

Neither the Company nor BG Fund ICAV has been, and neither will be, registered under the US Investment Company Act of 1940, as amended (the "Investment Company Act"). In addition the securities referenced in this announcement have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"). Consequently any such securities may not be offered, sold or otherwise transferred within the United States or to, or for the account or benefit of, US persons except in accordance with the Securities Act or an exemption therefrom and under circumstances which will not require the issuer of such securities to register under the Investment Company Act. No public offering of any securities will be made in the United States.

You should always bear in mind that:

all investment is subject to risk;

results in the past are no guarantee of future results;

the investment performance of BGHL may go down as well as up. You may not get back all of your original investment; and

if you are in any doubt about the contents of this communication or if you consider making an investment decision, you are advised to seek expert financial advice.

 

This communication is for information purposes only and the information contained in this communication should not be relied upon as a substitute for financial or other professional advice.

 

 

 

Attachment

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

FDA Greenlights Kisqali®: A Major Step for Breast Cancer Care

Updated Category News Views 203

Kisqali® Receives FDA Approval for Early Breast Cancer Treatment Novartis has some exciting news for oncology: the US Food and Drug Administration (FDA) has officially approved Kisqali® (ribociclib) as a treatment for patients diagnosed with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) stage II and III early breast cancer...

Continue Reading
Ålandsbanken Abp Launches SEK 350M Additional Tier 1 Notes Series

Updated Category News Views 162

Ålandsbanken Abp Issues SEK 350,000,000 Additional Tier 1 Notes Ålandsbanken Abp, a prominent player in the banking industry, recently made waves in the financial market by issuing Additional Tier 1 floating rate notes amounting to SEK 350,000,000. The issuance marks a significant step in Ålandsbanken's strategic move to strengthen its capital position and enhance its...

Continue Reading
Harbour BioMed's 2025 Achievements and Future Prospects

Updated Category News Views 249

Harbour BioMed Achieves Significant Milestones in Interim Results Harbour BioMed (HKEX: 02142) is a prominent biopharmaceutical company focused on developing innovative antibody therapeutics, particularly in the fields of immunology and oncology. The company shared its impressive interim results for the first half of the year, showcasing remarkable growth and strategic...

Continue Reading
Innovative Investment Fuels Okika Devices' Future Growth Strategy

Updated Category News Views 187

Strategic Investment Boosts Okika Devices Advancement Colorado ONE Fund, which is part of the ONE Funds initiative, has made a major investment in Okika Devices, a company recognized for its innovation in Field Programmable Analog Array (FPAA) technology. This investment aligns with Colorado ONE Fund's mission to support technologies that advance the local innovation...

Continue Reading
Investors Take Note: Legal Options for Shareholders Explored

Updated Category News Views 61

Exploring Legal Options for Investors in Major Companies In recent developments, Halper Sadeh LLC, a reputable law firm focusing on investor rights, is carefully examining three significant companies for potential violations of federal securities laws. This investigation centers around the actions and decisions made by these firms, which may affect shareholders' rights...

Continue Reading